Tumor-infiltrating lymphocytes

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
Jing Gao, Zhengyi Wang, Wenqing Jiang, Yanni Zhang, Zhen Meng, Yanling Niu, Zhen Sheng, Chan Chen, Xuejun Liu, Xi Chen, Chanjuan Liu, Keren Jia, Cheng Zhang, Haiyan Liao, Jaeho Jung, Eunsil Sung, Hyejin Chung, Jingwu Z. Zhang, Andrew X. Zhu, Lin Shen

Journal for ImmunoTherapy of Cancer Jun 2023, 11 (6) e006704; DOI: 10.1136/jitc-2023-006704
Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
João Manuel Santos, Camilla Heiniö, Victor Cervera-Carrascon, Dafne C A Quixabeira, Mikko Siurala, Riikka Havunen, Ralf Butzow, Sadia Zafar, Tanja de Gruijl, Heini Lassus, Anna Kanerva, Akseli Hemminki

Journal for ImmunoTherapy of Cancer Jan 2020, 8 (1) e000188; DOI: 10.1136/jitc-2019-000188
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, Kenneth Hess, Coya Tapia, Mingxuan Xu, Jordi Rodon Ahnert, Camilo Jimenez, Jeffrey E. Lee, Nancy D. Perrier, Russell R. Boraddus, Shubham Pant, Vivek Subbiah, David S. Hong, Abdulrazzak Zarifa, Siqing Fu, Daniel D. Karp, Funda Meric-Bernstam, Aung Naing

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 253; DOI: 10.1186/s40425-019-0722-x
What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO)
Paolo Antonio Ascierto, Giacomo Cartenì, Cesare Gridelli, Sandro Pignata, Antonio Pinto, Carmen Criscitiello, Luigi Buonaguro, Stefano Pepe, Roberto Mabilia, Vincenzo Montesarchio, Bruno Daniele, Sabino De Placido

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 41; DOI: 10.1186/s40425-016-0144-y
Application of the Immunoscore as prognostic tool for hepatocellular carcinoma
Annacarmen Petrizzo, Luigi Buonaguro

Journal for ImmunoTherapy of Cancer Dec 2016, 4 (1) 71; DOI: 10.1186/s40425-016-0182-5
Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis
Keith E. Steele, Tze Heng Tan, René Korn, Karma Dacosta, Charles Brown, Michael Kuziora, Johannes Zimmermann, Brian Laffin, Moritz Widmaier, Lorenz Rognoni, Ruben Cardenes, Katrin Schneider, Anmarie Boutrin, Philip Martin, Jiping Zha, Tobias Wiestler

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 20; DOI: 10.1186/s40425-018-0326-x
Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
Maartje W. Rohaan, Joost H. van den Berg, Pia Kvistborg, John B. A. G. Haanen

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 102; DOI: 10.1186/s40425-018-0391-1
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
Daniel E. Carvajal-Hausdorf, Nikita Mani, Vamsidhar Velcheti, Kurt A. Schalper, David L. Rimm

Journal for ImmunoTherapy of Cancer Dec 2017, 5 (1) 81; DOI: 10.1186/s40425-017-0285-7
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8⁺ T cells directly within the tumor microenvironment
Stefani Spranger, Holly K Koblish, Brendan Horton, Peggy A Scherle, Robert Newton, Thomas F Gajewski

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 3; DOI: 10.1186/2051-1426-2-3
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
Troels Holz Borch, Rikke Andersen, Eva Ellebaek, Özcan Met, Marco Donia, Inge Marie Svane

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000668; DOI: 10.1136/jitc-2020-000668

Log in using your username and password

Main menu

Log in using your username and password

You are here

Tumor-infiltrating lymphocytes